Prevalence of TMC278 (rilpivirine) associated mutations in the Frankfurt Resistance Database

Journal of Clinical Virology

Volumn 53, Issue 3, 2012, Pages 248-250

  Reinheimer, Claudia ^a   Doerr, Hans W ^a   Stürmer, Martin ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Drug resistance; Prevalence; Rilpivirine; TMC278

Indexed keywords

RILPIVIRINE;

ANTIVIRAL RESISTANCE; ARTICLE; CROSS RESISTANCE; HUMAN; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; VIRUS MUTATION; WILD TYPE;

CHI-SQUARE DISTRIBUTION; DATABASES, GENETIC; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; NITRILES; PREVALENCE; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84856964209     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.12.012     Document Type: Article

References (16)

1. Mehta U., Maartens G. Is it safe to switch between efavirenz and nevirapine in the event of toxicity?. Lancet Infect Dis 2007, 7(11):733-738.
2. Portilla J. Safety and tolerability of etravirine. Enferm Infecc Microbiol Clin 2009, 27(Suppl. 2):21-26.
3. Antinori A., Baldini F., Girardi E., Cingolani A., Zaccarelli M., Di Giambenedetto S., et al. Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy. AIDS 2001, 15(12):1579-1581.
4. Madruga J.V., Cahn P., Grinsztejn B., Haubrich R., Lalezari J., Mills A., et al. DUET-1 study group. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007, 370(9581):29-38.
5. Lazzarin A., Campbell T., Clotet B., Johnson M., Katlama C., Moll A., et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007, 370(9581):39-48.
6. Vingerhoets J., Tambuyzer L., Azijn H., Hoogstoel A., Nijs S., Peeters M., et al. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 2010, 24(4):503-514.
7. Schrijvers R., Ayele Desimmie B., Debyser Z. Rilpivirine: a step forward in tailored HIV treatment. Lancet 2011, 378(July (9787)):201-203.
8. Guillemont J., Pasquier E., Palandjian P., Vernier D., Gaurrand S., Lewi P.J., et al. Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1. J Med Chem 2005, 48:2072-2079.
9. Janssen P.A., Lewi P.J., Arnold E., Daeyaert F., de Jonge M., Heeres J., et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem 2005, 48:1901-1909.
10. Azijn H., Tirry I., Vingerhoets J., de Béthune M.P., Kraus G., Boven K., et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010, 54(2):718-727.
11. Rimsky L., Vingerhoets J., Van Eygen V., Eron J., Clotet B., Hoogstoel A., et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr 2011, (November). [Epub ahead of print].
12. Molina J.M., Cahn P., Grinsztejn B., Lazzarin A., Mills A., Saag M., et al. ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011, 378(9787):238-246.
13. Cohen C.J., Andrade-Villanueva J., Clotet B., Fourie J., Johnson M.A., Ruxrungtham K., et al. THRIVE study group. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011, 378(9787):229-237.
14. Stürmer M., Doerr H.W., Preiser W. Variety of interpretation systems for human immunodeficiency virus type 1 genotyping: confirmatory information or additional confusion?. Curr Drug Targets Infect Disord 2003, 3(4):373-382.
15. Stürmer M., Berger A., Doerr H.W. Modifications and substitutions of the RNA extraction module in the ViroSeq HIV-1 genotyping system version 2: effects on sensitivity and complexity of the assay. J Med Virol 2003, 71(4):475-479.
16. Fulco P.P., McNicholl I.R. Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents. Pharmacotherapy 2009, 29(3):281-294.